Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics intended to address unmet medical needs in important cardiovascular care markets. The Company’s development programs are primarily focused on the treatment of cardiovascular diseases. Its lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients to treat early cardiogenic shock and acute heart failure (AHF). Its Rostafuroxin is an investigational drug product candidate being developed for the treatment of hypertension in patients with a specific genetic profile. Its heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a (SERCA2a) activators. The Company is also conducting early exploratory research to assess potential product candidates, including oral and intravenous SERCA2a activator heart failure compounds.